Integrating Novel Therapies in Hemophilia in the Midst of Bridging Health Inequities

Estimated Time
1.0 hr

Release Date
May 15, 2024

Expiration Date
May 14, 2025

As the treatment armamentarium for patients with hemophilia continues to expand, there is an urgent need for healthcare providers to stay up-to-date on the latest advances so that they are prepared to integrate them into clinical practice. To bridge this gap, this interactive educational activity will provide a review of the science surrounding new and emerging hemophilia treatments and their mechanisms of action; recent safety and efficacy data from key clinical trials; and novel dosing strategies to mitigate adverse events. Engaging case-based discussions and insights on addressing common patient barriers and clinical challenges will be explored by expert faculty, including a guest spotlight offering the early perspective.  Thus, this educational initiative is designed to equip providers with the necessary tools to effectively navigate new and novel therapies, overcome patient-level barriers, and optimize adherence for improved patient outcomes.


Accreditation and Disclosure Information

Educational Objectives
After completing this activity, the participant should be better able to:

  • Appropriately select hemophilia treatment based on the latest clinical evidence on new and emerging therapies in accordance with clinical guidelines
  • Accurately identify symptoms and potential adverse events associated with the various treatment modalities for patients with hemophilia
  • Skillfully employ shared decision-making to screen for and address QoL concerns for patients with hemophilia
  • Formulate strategies to surmount barriers that hinder the delivery of optimal patient care across the continuum, including patients in rural communities, of female sex, and mild disease

Program Agenda 

  • The Right Treatment for the Right Patient: Integrating Novel Therapies into Clinical Practice
  • Managing the Diverse Account of Adverse Events With Treatment
  • Elevating Patient Care: Addressing Barriers and Supporting Patients in the Care Continuum

Target Audience
This activity is intended for hematologists/oncologists, PAs, NPs, nurses, pharmacists, and individuals that practice at hemophilia treatment centers (HTC) engaged in the care of patients with hemophilia.

Accreditation, Support and Credit


Joint Accreditation with Commendation Logo

In support of improving patient care, Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
Medical Learning Institute, Inc. (MLI) designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).

Physician Associate
Medical Learning Institute, Inc. has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until May 14, 2025. PAs should only claim credit commensurate with the extent of their participation

Nursing Continuing Professional Development
Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour and 0.66 contact hour in the area of pharmacology.

Continuing Pharmacy Education
Medical Learning Institute, Inc. designates this continuing education activity for 1.0 contact hour (0.1 CEU) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA0007322-0000-24-048-H01-P
Type of Activity: Application

Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.


Commercial Support Statement
This activity is supported by an educational grant from Novo Nordisk Inc.

Disclosure & Conflict of Interest Policy
Medical Learning Institute, Inc. is committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, MLI requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to MLI policy. These disclosures will be provided to learners prior to the start of the CE activity.

Faculty Disclosures
Tammuella E. Chrisentery-Singleton, MD

Chief, Pediatric Hematology
Chief Science Officer
American Hemostasis and Thrombosis Network
Rochester, NY
Co-Director, Hemostasis & Thrombosis Program
Ochsner Clinic Foundation
New Orleans, LA

Tammuella E. Chrisentery-Singleton, MD, has a financial interest/relationship or affiliation in the form of: Consultant/Advisor: Octapharma, Bayer, Novo Nordisk, CSL Behring, Kedrion, Genentech, BioMarin, Takeda, HEMA Biologics, Pfizer
Speakers’ Bureau: Octapharma, Bayer, Novo Nordisk, CSL Behring, Kedrion, Genentech, BioMarin, Takeda, HEMA Biologics, Pfizer

Alan E. Mast, MD, PhD
Leader, Thrombosis and Hemostasis Program
Walter A. Schroeder Endowed Chair for Blood Research
Senior Investigator and Program Leader
Versiti Blood Research Institute
Milwaukee, WI

Alan E. Mast, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant/Advisor: Novo Nordisk
Research Funding: Novo Nordisk

Allison P. Wheeler, MD, MSCI

Associate Professor
Vanderbilt University Medical Center
Departments of Clinical Pathology & Pediatric Hematology
Director of Research for Benign Hematology
Nashville, TN

Allison P. Wheeler, MD, MSCI, has a financial interest/relationship or affiliation in the form of:
Consultant/Advisor: CSL Behring, Bayer, Novo Nordisk, Canofi, Genentech, Takeda, Pfizer, Vega Therapeutics
Research Funding: Octapharma, Novo Nordisk, Sanofi, CSL Behring, Vega Therapeutics

Guest Commentator
Shannon C. Walker, MD

Assistant Professor, Vanderbilt University Medical Center
Department of Pathology, Microbiology, and Immunology – Transfusion Medicine
Department of Pediatrics – Vanderbilt Vaccine Research Program and Pediatric Hematology/Oncology
Nashville, TN

Shannon C. Walker, MD, has no relevant financial relationships with ineligible companies to disclose for this educational activity.

All of the relevant financial relationships of individuals for this activity have been mitigated.

Planning Committee and Content/Peer Reviewers
The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, do not have any relevant financial relationships to disclose with ineligible companies unless listed below.

Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Method of Participation
There are no fees for participating in or receiving credit for this CE activity. In order to receive credit, learners must participate in the entire CE activity, complete the activity evaluation form and your certificate of credit will be generated. You will receive your certificate from Medical Learning Institute, Inc.

For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

If you have questions regarding your certificate, please contact via email at

For Physicians, if requesting MOC credit, the post-test and evaluation are required in their entirety as well as your ABIM ID number, DOB (MM/DD), and a score of 70% or higher is needed to obtain MOC credit.

For Pharmacists, MLI will accept your completed evaluation form for up to 30 days post-activity and will report your participation to the NABP only if you provide your NABP e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your participation record at the NABP website:

About This Activity
Medical Learning Institute, Inc. is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of this activity is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of Medical Learning Institute, Inc.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of Medical Learning Institute, Inc. or any of its partners, providers, and/or supporters.

Copyright © 2024 Medical Learning Institute, Inc. All Rights Reserved.